NCT04141709Active, not recruiting
Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer
Effektivität Und Toxizität Einer Perkutanen Hochdosierten Strahlentherapie Bei Patienten Mit Oligometastasen Eines Kastrationsresistenten Prostatakarzinoms
Source: ClinicalTrials.gov · Last updated 1 Sept 2026
Brief summary (registry, in English)
The purpose of this randomized trial is to investigate the efficacy and toxicity of percutaneous high-dose radiotherapy in patients with oligometastases of hormone refractory prostate cancer. The effectiveness will be tested in comparison to an observation group, in which no further therapy is initially given. Treatment can be stereotactically hypofractionated or conventionally fractionated.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- First submitted
- 24 Oct 2019
- Start date
- 1 Dec 2019
- Primary completion date
- 28 Apr 2027
- Lead sponsor
- Technische Universität Dresden
- Diseases
- Prostate cancer
- NCT number
- NCT04141709
What you commit to
- Study type: Interventional
- Planned participants: 66
- From 1 Dec 2019 to the primary completion date, 28 Apr 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Severe concomitant disease that limits further life expectancy to \< 5 years according to the physician's assessment.
- previous taxane-containing chemotherapy
Other
- PSA \> 20ng/ml, testosterone \>50 dl or \>1,73nmol/l
- visceral metastasis (e.g. lung, liver, brain)
- lack of compliance
Who the study is looking for
- Patient with good general condition (WHO 0-1)
- Histologically confirmed prostate carcinoma
- After definitive local therapy, e.g. radical prostatectomy or definitive radiotherapy (also after neo-adjuvant hormone therapy, after postoperative radiotherapy).
- PSA progression under ongoing androgen deprivation (defined as three consecutive increasing PSA values at intervals of \> 4 weeks and testosterone in the castration area \<50ng/dl or \<1.73nmol/)
- Minimum duration of androgen deprivation 6 months before inclusion in study
- Present complete staging (max. 6 weeks old), preferably by means of PET hybrid imaging with prostate-specific PET tracer
- Imaging detection of individual active or progressive metastases (max. 5, depending on location) that are accessible to local ablative radiotherapy (histological confirmation of the metastases is not required)
- No parallel participation to further clinical therapy trials up to 4 weeks before and after radiation therapy
- Individual case discussion in an interdisciplinary tumor board
- Patient's ability to consent and written consent
Criteria the registry did not label
- Indication:
- Oligometastases (1-5) in castration-resistant prostate carcinoma
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden Coordinator of this site? Confirm its status | Dresden | Germany | Unknown status |
| University Medical Center Freiburg, Department of Radiation Oncology Coordinator of this site? Confirm its status | Freiburg im Breisgau | Germany | Unknown status |
| University Hospital Heidelberg, Department of Radiation Oncology Coordinator of this site? Confirm its status | Heidelberg | Germany | Unknown status |
| University Clinic Tübingen, Clinic for Radiation Oncology Coordinator of this site? Confirm its status | Tübingen | Germany | Unknown status |
Related publications
- Ablative radiotherapy in castration-resistant prostate cancer.BJU Int · 2026 · PMID 42389925
This page is information, not medical advice. Discuss any trial with your doctor.